Research

TRACTS, based at the VA Boston Healthcare System, is carrying out one of the most comprehensive VA studies on blast injuries on post-9-11 Veterans.

A VA pilot study yielded promising results on a device to detect early diabetic retinopathy and a drug to potentially reverse the symptoms.

A survey of more than 400 Veteran users of upper-limb prostheses found little difference in satisfaction based on device type. Overall rankings fell just shy of "satisfied."

A new study funded by the National Institutes of Health and the Department of Defense found similar survival rates among black and white patients with prostate cancer receiving care at VA.

In 2015, VA launched the Technology-based Eye Care Services program. It now serves 22 sites, and researchers are helping to ensure optimal effectiveness.

Hear the latest on treating prostate cancer. Check out a Feb. 24 lecture, online or in person at VA headquarters, on precision oncology for Veterans.

When it comes to exploring new ways to care for patients, VA has a unique advantage: We’re the nation’s largest integrated health care system. And that means we can access the nation’s largest store of voluntary patient data.

LIMBIC, funded by VA and Defense, is the world’s largest research cohort of current and former military members that is dedicated to the study of mild traumatic brain injury.

A recent study found that non-drug therapies given to service members with chronic pain may reduce the risk of long-term adverse outcomes, such as alcohol and drug disorder or suicide attempts.

Dr. Mark Logue, an Army Veteran, is a statistician in the National Center for PTSD at the VA Boston Healthcare System. His research interests include the genetics of brain disorders such as PTSD, Alzheimer’s disease, and anxiety.

A VA study has shown that frail surgery patients may be at higher risk than previously thought.

A partnership between VA and the Prostate Cancer Foundation is speeding the development of treatments and cures for Veterans with aggressive—or metastatic—prostate cancer through precision oncology.